0.5% in placebo) and increased lean mass (3.6% vs
However, due to discrepancies in findings from clinical trials, real-world data, and fundamental research, definitive recommendations for diabetic retinopathy screening prior to GLP-1 RA treatment initiation remain elusive
The most frequently reported side effects were mild to moderate nausea and diarrhea
Also of concern is the loss of lean muscle mass that can occur during weight loss on the drug
Ayala JE, Bracy DP, James FD, Burmeister MA, Wasserman DH, Drucker DJ
7, 2025 Journal of Obesity, A Comprehensive Review on Weight Gain following Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists for Obesity, May 10, 2024 KFF, Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford, Nov